In an effort to strengthen health outcomes for patients in low resource settings, The Max Foundation and its subsidiary, MaxAid, have signed Collaboration Agreements with 140 individual hematologists and oncologists from leading National Cancer Institutes and clinics in 60 low- and middle-income countries. With the formal establishment of this network, The Max Foundation completes its validated supply chain into each of the countries, providing a safe environment through which to channel humanitarian donations of cancer treatment with end-to-end controls.
“Oncologists and hematologists from these leading cancer centers are the true heroes of our humanitarian treatment access success story,” said Pat Garcia-Gonzalez, CEO of The Max Foundation. “Their dedication to their patients and commitment to our partnership allows us to prevent unnecessary and premature cancer deaths. Working in a challenging environment, their personal contributions go well beyond treatment management and inspire us to do our best to support their patients’ needs.”
Dr. Damira Bayzakova, Kyrgyzstan, adds that “Providing lifesaving treatment to one patient does not save the life of one patient – it saves the lives of the dozens of small children and elderly family members who depend on that patient for their survival.”
The Max Foundation aims to sign collaboration agreements with a total of 350 hematologists and oncologists from more than 70 countries in 2017.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
We’re pleased to share that the New England Journal of Medicine has published our “Letter to the Editor” on treatment-free remission for chronic myeloid leukemia in low- and middle-income countries! It was written in collaboration with Dr. Jerry Radich from the Fred Hutchinson Cancer Research Center and partner physicians from Armenia, the Dominican Republic, El….
Max adds three new members to the Board of Directors, increasing the seats from eight to 11 In addition, Max has added 10 new team members in 2024 to support growing patient reach, collaboration with partners, and new disease areas This expansion will ensure Max can meet its strategic goals, including treating more patients, amplifying….
In 2017 The Max Foundation, through its subsidiary MaxAid, and Novartis have renewed their commitment to patients by launching CMLPath to Care™ a new collaboration aimed at providing humanitarian access to treatment for CML and other rare cancers for those patients for whom no other form of local treatment access exists today. CMLPath to Care consists of humanitarian product donations and funding support from Novartis to Max, and an innovative new distribution model developed and implemented by Max and its international distributor, under the Max Access Solution umbrella.
